Feasibility of Intravenous Iron Isomaltoside to Improve Anemia and Quality of Life During Palliative Chemotherapy for Esophagogastric Adenocarcinoma

References

• Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, et al.: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40, 2293–2306, 2004.
   PubMed Web of Science ®Google Scholar
• Groopman JE and Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91, 1616–1634, 1999.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Muldur E, Endler G, and Hubl W.: Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24, 1886–1892, 2013.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355, 11–20, 2006.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, et al.: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 3, CD004064, 2010.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A, and Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91, 2214–2221, 2001.
   PubMed Web of Science ®Google Scholar
• Harper P and Littlewood T: Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology 69, 2–7, 2005.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Evstatiev R, Kornek G, Aapro M, Bauernhofer T, et al.: Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr 127, 907–919, 2015.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Holden SA, al-Achi A, and Herman TS: Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50, 3339–3344, 1990.
   PubMed Web of Science ®Google Scholar
• Van Belle SJ and Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 47, 1–11, 2003.
   PubMed Web of Science ®Google Scholar
• Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, et al.: Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 11, 971–975, 2000.
   PubMed Web of Science ®Google Scholar
• Ludwig H and Strasser K: Symptomatology of anemia. Semin Oncol 28, 7–14, 2001.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, et al.: Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 168, 2377–2381, 2008.
   PubMed Web of Science ®Google Scholar
• Gordon MS: Managing anemia in the cancer patient: old problems, future solutions. Oncologist 7, 331–341, 2002.
   PubMed Web of Science ®Google Scholar
• Grotto HZ: Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 25, 12–21, 2008.
   PubMed Web of Science ®Google Scholar
• Adamson JW: The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program, 159–165, 2008. doi:10.1182/asheducation-2008.1.159
   PubMedGoogle Scholar
• Goodnough LT, Nemeth E, and Ganz T: Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116, 4754–4761, 2010.
   PubMed Web of Science ®Google Scholar
• Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, and Laufman LR; Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12, 231–242, 2007.
   PubMed Web of Science ®Google Scholar
• Aapro M, Osterborg A, Gascon P, Ludwig H, and Beguin Y: Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 23, 1954–1962, 2012.
   PubMed Web of Science ®Google Scholar
• Steinmetz HT: The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol 3, 177–191, 2012.
   PubMedGoogle Scholar
• Demetri GD, Kris M, Wade J, Degos L, and Cella D: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16, 3412–3425, 1998.
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, et al.: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19, 2875–2882, 2001.
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, et al.: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19, 2865–2874, 2001.
   PubMed Web of Science ®Google Scholar
• Glaspy J: The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem. Semin Hematol 34, 20–26, 1997.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, et al.: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373, 1532–1542, 2009.
   PubMed Web of Science ®Google Scholar
• Spivak JL: The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 5, 543–555, 2005.
   PubMed Web of Science ®Google Scholar
• Henry DH, Dahl NV, and Auerbach MA: Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 87, 308–310, 2012.
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Somerfield MR, et al.: American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Oncol Pract 6, 317–320, 2010.
   PubMedGoogle Scholar
• Schrijvers D, De Samblanx H, Roila F, and E.G.W. Group: Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21, v244–v247, 2010.
   PubMed Web of Science ®Google Scholar
• Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, et al.: Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21, 627–632, 2007.
   PubMed Web of Science ®Google Scholar
• Rodgers 3rd GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, et al.: Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 10, 628–653, 2012.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, et al.: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43, 258–270, 2007.
   PubMed Web of Science ®Google Scholar
• Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, et al.: Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 24, 475–482, 2013.
   PubMed Web of Science ®Google Scholar
• Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, et al.: Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 105, 199–204, 2007.
   PubMed Web of Science ®Google Scholar
• Dangsuwan P and Manchana T: Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 116, 522–525, 2010.
   PubMed Web of Science ®Google Scholar
• Athibovonsuk P, Manchana T, and Sirisabya N: Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol 131, 679–682, 2013.
   PubMed Web of Science ®Google Scholar
• Hedenus M, Karlsson T, Ludwig H, Rzychon B, Felder M, et al.: Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol 31, 302, 2014.
   PubMed Web of Science ®Google Scholar
• Ganzoni AM: Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 100, 301–303, 1970.
   PubMedGoogle Scholar
• Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34, 13–19, 1997.
   PubMed Web of Science ®Google Scholar
• EuroQol G: EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16, 199–208, 1990.
   PubMed Web of Science ®Google Scholar
• Johnston BC, Ebrahim S, Carrasco-Labra A, Furukawa TA, Patrick DL, et al.: Minimally important difference estimates and methods: a protocol. BMJ Open 5, e007953, 2015.
   PubMed Web of Science ®Google Scholar
• Lancaster GA, Dodd S, and Williamson PR: Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 10, 307–312, 2004.
   PubMed Web of Science ®Google Scholar
• Chadwick C, Varagunam M, Brand C, and Cromwell D: 2016 Annual Report of the National Oesophago-Gastric Cancer Audit (NOGCA). HQIP, 2016. http://www.hqip.org.uk/wp-content/uploads/2018/02/national-oesphago-gastric-cancer-audit-2016.pdf
   Google Scholar
• Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, et al.: FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 141, 846 e1-2–853 e1-2, 2011.
   Web of Science ®Google Scholar
• Cella D, Kallich J, McDermott A, and Xu X: The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15, 979–986, 2004.
   PubMed Web of Science ®Google Scholar
• Yakymenko D, Frandsen KB, Christensen IJ, Norgaard A, Johansson PI, et al.: Randomised feasibility study of a more liberal haemoglobin trigger for red blood cell transfusion compared to standard practice in anaemic cancer patients treated with chemotherapy. Transfus Med, 28, 208–215, 2018.
   PubMed Web of Science ®Google Scholar
• Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, et al.: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95, 888–895, 2002.
   PubMed Web of Science ®Google Scholar
• Auerbach M and Macdougall IC: Safety of intravenous iron formulations: facts and folklore. Blood Transfus 12, 296–300, 2014.
   PubMed Web of Science ®Google Scholar